BUZZ - Market View: The new generation of drugs boosts Eli Lilly's growth outlook

October 30 - ** Eli Lilly (LLY.N) raised its full-year revenue forecast (link) by $5 billion on Thursday, and third-quarter profit exceeded Wall Street expectations, thanks to strong demand for its weight loss therapies

** According to LSEG data, the median target price among the 33 brokerages covering the stock is $1,410

New pipeline catalysts

** Jefferies (maintains "Buy" rating, target price: $1,610) said that driven by pricing and volume growth, Eli Lilly's (LLY) GLP-1 and obesity business lines may continue to outperform in 2026 and beyond, while opportunities in the international obesity market and the "Medicare Bridge Program" will provide further upside

** Truist Securities ("Buy", target price: $1,612) said the company's ever-expanding diabetes and obesity drug portfolio—including pipeline therapies such as retatrutide and EloraTZP (a new generation obesity drug)—should help maintain its market leadership, while advances in neuroscience, immunology, and oncology will support company growth

** JPMorgan ("Overweight", target price: $1,650) said Eli Lilly (LLY) remains its top pick, expecting further upside as the company expands its lead in the incretin market and achieves key pipeline milestones in multiple non-obesity areas

** Morningstar (fair value: $980) said that as the company continues to raise the standards for both therapeutic efficacy and tolerability, the pipeline drugs EloraTZP and retatrutide are expected to become key growth drivers for LLY

(For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack needed context, Reuters does not guarantee the accuracy of this translated text and provides it for readers' convenience only. Reuters accepts no responsibility for any damage or loss arising from the use of automated translation.)